Prasanna Ananth1, Patrice Melvin2, Chris Feudtner3, Joanne Wolfe4, Jay G Berry5. 1. Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, prasanna.ananth@childrens.harvard.edu. 2. Center for Patient Safety and Quality Research, Boston Children's Hospital, Boston, Massachusetts; 3. Pediatric Advanced Care Team, The Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Division of Pediatric Palliative Care, Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, and. 5. Division of General Pediatrics, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts;
Abstract
BACKGROUND AND OBJECTIVES: Although many adults experience resource-intensive and costly health care in the last year of life, less is known about these health care experiences in children with life-threatening complex chronic conditions (LT-CCCs). We assessed hospital resource use in children by type and number of LT-CCCs. METHODS: A retrospective analysis of 1252 children with LT-CCCs, ages 1 to 18 years, who died in 2012 within 40 US children's hospitals of the Pediatric Health Information System database. LT-CCCs were identified with International Classification of Diseases, 9th Revision, Clinical Modification codes. Using generalized linear models, we assessed hospital admissions, days, costs, and interventions (mechanical ventilation and surgeries) in the last year of life by type and number of LT-CCCs. RESULTS: In the last year of life, children with LT-CCCs experienced a median of 2 admissions (interquartile range [IQR] 1-5), 27 hospital days (IQR 7-84), and $142 562 (IQR $45 270-$410 087) in hospital costs. During the terminal admission, 76% (n = 946) were mechanically ventilated; 36% (n = 453) underwent surgery. Hospital use was greatest (P < .001) among children with hematologic/immunologic conditions (99 hospital days [IQR 51-146]; cost = $504 145 [IQR $250 147-$879 331]) and children with ≥3 LT-CCCs (75 hospital days [IQR 28-132]; cost = $341 222 [IQR $146 698-$686 585]). CONCLUSIONS: Hospital use for children with LT-CCCs in the last year of life varies significantly across the type and number of conditions. Children with hematologic/immunologic or multiple conditions have the greatest hospital use. This information may be useful for clinicians striving to improve care for children with LT-CCCs nearing the end of life.
BACKGROUND AND OBJECTIVES: Although many adults experience resource-intensive and costly health care in the last year of life, less is known about these health care experiences in children with life-threatening complex chronic conditions (LT-CCCs). We assessed hospital resource use in children by type and number of LT-CCCs. METHODS: A retrospective analysis of 1252 children with LT-CCCs, ages 1 to 18 years, who died in 2012 within 40 US children's hospitals of the Pediatric Health Information System database. LT-CCCs were identified with International Classification of Diseases, 9th Revision, Clinical Modification codes. Using generalized linear models, we assessed hospital admissions, days, costs, and interventions (mechanical ventilation and surgeries) in the last year of life by type and number of LT-CCCs. RESULTS: In the last year of life, children with LT-CCCs experienced a median of 2 admissions (interquartile range [IQR] 1-5), 27 hospital days (IQR 7-84), and $142 562 (IQR $45 270-$410 087) in hospital costs. During the terminal admission, 76% (n = 946) were mechanically ventilated; 36% (n = 453) underwent surgery. Hospital use was greatest (P < .001) among children with hematologic/immunologic conditions (99 hospital days [IQR 51-146]; cost = $504 145 [IQR $250 147-$879 331]) and children with ≥3 LT-CCCs (75 hospital days [IQR 28-132]; cost = $341 222 [IQR $146 698-$686 585]). CONCLUSIONS: Hospital use for children with LT-CCCs in the last year of life varies significantly across the type and number of conditions. Children with hematologic/immunologic or multiple conditions have the greatest hospital use. This information may be useful for clinicians striving to improve care for children with LT-CCCs nearing the end of life.
Authors: Jay G Berry; Sonja I Ziniel; Linda Freeman; William Kaplan; Richard Antonelli; James Gay; Eric A Coleman; Stephanie Porter; Don Goldmann Journal: Int J Qual Health Care Date: 2013-08-20 Impact factor: 2.038
Authors: Alison E Overman; Meixia Liu; Stephen C Kurachek; Michael R Shreve; Roy C Maynard; Mark C Mammel; Brooke M Moore Journal: Pediatrics Date: 2013-04-08 Impact factor: 7.124
Authors: David Fox; Elizabeth J Campagna; Joel Friedlander; David A Partrick; Daniel I Rees; Allison Kempe Journal: J Pediatr Gastroenterol Nutr Date: 2014-11 Impact factor: 2.839
Authors: Jay G Berry; Annapurna Poduri; Joshua L Bonkowsky; Jing Zhou; Dionne A Graham; Chelsea Welch; Heather Putney; Rajendu Srivastava Journal: PLoS Med Date: 2012-01-17 Impact factor: 11.069
Authors: Jay G Berry; Michael Glotzbecker; Jonathan Rodean; Izabela Leahy; Matt Hall; Lynne Ferrari Journal: Pediatrics Date: 2017-02-02 Impact factor: 7.124
Authors: Ryan J Coller; Thomas S Klitzner; Carlos F Lerner; Bergen B Nelson; Lindsey R Thompson; Qianqian Zhao; Adrianna A Saenz; Siem Ia; Jessica Flores-Vazquez; Paul J Chung Journal: Pediatrics Date: 2018-07-11 Impact factor: 7.124
Authors: Eve Namisango; Katherine Bristowe; Matthew J Allsop; Fliss E M Murtagh; Melanie Abas; Irene J Higginson; Julia Downing; Richard Harding Journal: Patient Date: 2019-02 Impact factor: 3.883